ATA Guidelines Tools

Thyroid Disease During Pregnancy

American Thyroid Association Quick-Reference GUIDELINES Apps

Issue link: https://eguideline.guidelinecentral.com/i/789888

Contents of this Issue

Navigation

Page 16 of 19

17 Postpartum Thyroiditis (PPT) Î All patients with depression, including postpartum depression, should be screened for thyroid dysfunction. (S-L) Î During the thyrotoxic phase of PPT, symptomatic women may be treated with beta-blockers. A beta-blocker which is safe for lactating women, such as propranolol or metoprolol, at the lowest possible dose to alleviate symptoms, is the treatment of choice. Therapy is typically required for a few weeks. (S-M) Î Antithyroid drugs are NOT recommended for the treatment of the thyrotoxic phase of PPT. (S-H) Î Following the resolution of the thyrotoxic phase of PPT, serum TSH should be measured in approximately 4–8 weeks (or if new symptoms develop) to screen for the hypothyroid phase. (S-H) Î LT4 should be considered for women with symptomatic hypothyroidism due to PPT. If treatment is not initiated, their TSH level should be repeated every 4–8 weeks until thyroid function normalizes. LT4 should also be started in hypothyroid women who are attempting pregnancy or who are breastfeeding. (W-M) Î If LT4 is initiated for PPT, discontinuation of therapy should be attempted after 12 months. Tapering of LT4 should be avoided when a woman is actively attempting pregnancy or is pregnant. (W-L) Î Women with a prior history of PPT should have TSH testing annually to evaluate for the development of permanent hypothyroidism. (S-H) Î Treatment of euthyroid thyroid antibody-positive pregnant woman with either LT4 or iodine to prevent PPT is ineffective and is NOT recommended. (S-H)

Articles in this issue

Archives of this issue

view archives of ATA Guidelines Tools - Thyroid Disease During Pregnancy